BioSig Technologies, Inc. (BSGM)
NASDAQ: BSGM · Real-Time Price · USD
1.870
-0.080 (-4.10%)
At close: Nov 20, 2024, 4:00 PM
1.920
+0.050 (2.67%)
After-hours: Nov 20, 2024, 4:03 PM EST

Company Description

BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body’s electrical signals starting with heart rhythms.

It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines.

The company’s product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system.

BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

BioSig Technologies, Inc.
BioSig Technologies logo
Country United States
Founded 2009
Industry Medical Devices
Sector Healthcare
Employees 4
CEO Anthony Amato

Contact Details

Address:
55 Greens Farms Road, 1st Floor
Westport, Connecticut 06880
United States
Phone 203 409 5444
Website biosig.com

Stock Details

Ticker Symbol BSGM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001530766
CUSIP Number 09073N201
ISIN Number US09073N3008
Employer ID 26-4333375
SIC Code 3845

Key Executives

Name Position
Anthony Amato Chief Executive Officer, Chairman and Member of Advisory Board
Frederick D. Hrkac President, Principal Executive Officer, Executive Vice President and Director
Ferdinand Groenewald Interim Chief Financial Officer and Principal Accounting Officer
Dr. Budimir S. Drakulic Ph.D. Chief Scientist

Latest SEC Filings

Date Type Title
Nov 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 18, 2024 DEF 14A Other definitive proxy statements
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 8, 2024 PRE 14A Other preliminary proxy statements
Oct 29, 2024 8-K Current Report
Oct 22, 2024 8-K Current Report
Sep 13, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report